Drug Type Trispecific T-cell engager (TriTE) |
Synonyms IM 8319, IM8319 |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants), CD8 stimulants(Cluster of differentiation 8 stimulants) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Lymphoma | Preclinical | CN | 22 Mar 2024 | |
B-Cell Leukemia | Preclinical | CN | - | |
CD20 Positive B-Cell Non-Hodgkin Lymphoma | Preclinical | CN | - |